Alnylam Pharmaceuticals (alny 1 09/15/27)
13F holders, Q2 2026 (June 30)5holders −4
0new positions
4sold out
$1.20avg. 13F price*
At the end of Q2 2026, 5 institutions reported holding Alnylam Pharmaceuticals (alny 1 09/15/27) in their 13F filings, down 4 from Q1 2026. 0 opened new positions and 4 sold out. The largest holders were Sei Investments Co. ($302K), Bank of New York Mellon Corp ($259K) and Oppenheimer Asset Management Inc. ($96K).
- Company
- Alnylam Pharmaceuticals (alny 1 09/15/27)
- CUSIP
- 02043QAB3
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 4 | $19.4M |
All 13F filers, Q1 2026 → Q2 2026: 13,863,860 shares sold, net −13,863,860 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Sei Investments Co. | 0.00% | No change | 251,000 | $302K |
| Bank of New York Mellon Corp | 0.00% | No change | 215,000 | $259K |
| Oppenheimer Asset Management Inc. | 0.00% | Reduce -1.2% | 80,000 | $96K |
| Boussard & Gavaudan Gestion Sas | 0.00% | — | 24,763 | $30K |
| Stephens Inc. | 0.00% | No change | 24,000 | $29K |
"% of holder's portfolio" is ALNYLAM PHARMACEUTICALS (ALNY 1 09/15/27)'s weight in each manager's 13F, not the share of Alnylam Pharmaceuticals (alny 1 09/15/27) the manager owns.